Roche grabs Bicycle Therapeutics’ platform
Roche AGs has paid US$30m upfront in a potential US$1.7bn deal to get access to Bicycle Therapeutics plc’s technology platform to target immune checkpoints.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2000 entries already.
Entries by Thomas Gabrielczyk
Human iPSC derived neurons for research and HTS
Widespread use of human induced pluripotent stem cell (hiPSC) derived mature cell types is restricted by complex differentiation protocols and inefficient reprogramming methods. By applying a novel gene engineering approach, opti-oxTM, to cellular reprogramming these restrictions have been largely overcome. This proprietary technology enables precise reprogramming and homogeneous differentiation of entire stem cell cultures into any desired cell type.
Microglia inhibitor stops neuronal cell death after TBI
Post-Brexit budget drives cuts in Horizon Europe
Negotiations of the EU Council on the EU’s seven-year budget have failed, putting R&D funding at risk for significant cuts.
Royal DSM acquires Glycom A/S for €765m
Royal DSM NV has entered the growing market of human milk oligosaccharides (HMO) taking over the producer of recombinant 2′-fucosyl lactose, Danish Glycom A/S.
Immatics Biotechnologies lands €1.1bn deal with GSK
US-German immunooncology specialist Immatics Biotechnologies GmbH has licensed two of its TCR-T programs to GlaxoSmithKline for US$50m upfront.
KKR backs Belgian tech provider Univercells SA
Univercells S.A. cashes in up to €50m from the KKR subsidiary Gamma Bioscience to advance its gene and cell therapy manufacturing platform.
EU diagnostic labs prepared for Sars-CoV-2
Shortly before a EU health ministers discuss the spread of the Chinese coronavirus, EU diagnostic labs have considered themselves prepared for a possible Sars-CoV-2 epidemic.
PharmaMar/Jazz Pharmaceuticals get NDA priority for lung cancer drug
Diabetes combo improves regeneration of beta cells
Using a combination of approved diabetes drugs, a Swiss-US research team was able to support the regeneration of insulin-secreting cells in the pancreas.